A detailed history of Ensign Peak Advisors, Inc transactions in Eli Lilly & CO stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 876,412 shares of LLY stock, worth $660 Million. This represents 1.38% of its overall portfolio holdings.

Number of Shares
876,412
Previous 891,915 1.74%
Holding current value
$660 Million
Previous $808 Million 3.85%
% of portfolio
1.38%
Previous 1.49%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$772.14 - $960.02 $12 Million - $14.9 Million
-15,503 Reduced 1.74%
876,412 $776 Million
Q2 2024

Aug 13, 2024

SELL
$724.87 - $909.04 $25.6 Million - $32.1 Million
-35,339 Reduced 3.81%
891,915 $808 Million
Q1 2024

May 14, 2024

BUY
$592.2 - $792.28 $131 Million - $175 Million
221,327 Added 31.35%
927,254 $721 Million
Q4 2023

Feb 14, 2024

BUY
$525.19 - $619.13 $61.8 Million - $72.9 Million
117,708 Added 20.01%
705,927 $411 Million
Q3 2023

Nov 13, 2023

SELL
$434.7 - $599.3 $125 Million - $173 Million
-288,166 Reduced 32.88%
588,219 $316 Million
Q2 2023

Aug 14, 2023

BUY
$350.74 - $468.98 $58.7 Million - $78.5 Million
167,426 Added 23.62%
876,385 $411 Million
Q1 2023

May 15, 2023

BUY
$310.63 - $364.82 $90.3 Million - $106 Million
290,645 Added 69.48%
708,959 $243 Million
Q4 2022

Feb 13, 2023

BUY
$321.55 - $374.67 $9.71 Million - $11.3 Million
30,207 Added 7.78%
418,314 $153 Million
Q3 2022

Nov 14, 2022

BUY
$296.48 - $337.87 $32.5 Million - $37 Million
109,602 Added 39.35%
388,107 $125 Million
Q2 2022

Aug 12, 2022

SELL
$278.73 - $327.27 $61.9 Million - $72.6 Million
-221,910 Reduced 44.35%
278,505 $90.3 Million
Q1 2022

May 16, 2022

SELL
$234.69 - $291.66 $33.7 Million - $41.9 Million
-143,781 Reduced 22.32%
500,415 $143 Million
Q4 2021

Feb 11, 2022

SELL
$224.85 - $279.04 $7.54 Million - $9.36 Million
-33,543 Reduced 4.95%
644,196 $178 Million
Q3 2021

Nov 12, 2021

SELL
$221.6 - $272.71 $72.6 Million - $89.3 Million
-327,396 Reduced 32.57%
677,739 $157 Million
Q2 2021

Aug 13, 2021

SELL
$180.55 - $233.54 $8.1 Million - $10.5 Million
-44,851 Reduced 4.27%
1,005,135 $231 Million
Q1 2021

May 12, 2021

BUY
$164.32 - $212.72 $45.8 Million - $59.3 Million
278,594 Added 36.12%
1,049,986 $196 Million
Q4 2020

Feb 12, 2021

SELL
$130.46 - $172.63 $9.85 Million - $13 Million
-75,535 Reduced 8.92%
771,392 $130 Million
Q3 2020

Nov 12, 2020

BUY
$146.22 - $169.13 $4.66 Million - $5.39 Million
31,871 Added 3.91%
846,927 $125 Million
Q2 2020

Aug 12, 2020

BUY
$136.42 - $164.18 $75 Million - $90.3 Million
549,775 Added 207.24%
815,056 $134 Million
Q1 2020

May 11, 2020

SELL
$119.05 - $147.35 $3.72 Million - $4.61 Million
-31,253 Reduced 10.54%
265,281 $36.8 Million
Q4 2019

Feb 14, 2020

BUY
$106.92 - $132.43 $31.7 Million - $39.3 Million
296,534 New
296,534 $39 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $716B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.